GLP-1 Receptor Agonists: The Reinforcements The FLOW trial, also published in the New England Journal of Medicine, tested semaglutide (Ozempic) in 3,533 patients with type 2 diabetes and CKD (Perkovic et al., 2024)
For non-tested athletes or physique-focused bodybuilders, tesamorelin may serve as a powerful addition to their enhancement toolbox
However, in specifically designed placebo-controlled studies of GLP-1 RAs among patients with HFrEF, there were no improvements in HRQoL
Moreover, a comparable study has investigated the therapeutic potential of Bifidobacterium breve , Bifidobacterium longum , Bifidobacterium lactis , and Bifidobacterium bifidum in modulating glioma tumour progression [273]
More research is needed before GLP-1 drugs can be prescribed as a treatment for alcohol use disorder